Microarray data accession number GSE19978.

Introduction
============

Plant vascular systems are composed of xylem, phloem and procambium/cambium, which is the vascular stem cell giving rise to xylem and phloem cells. Continuous xylem strands provide pathways for water, nutrients and signaling molecules and also function in mechanical support of the plant body. Xylem vessels are classified into two types, protoxylem vessels with a spiral thickening, and metaxylem vessels with a reticulate and pitted thickening pattern. In Arabidopsis roots, two protoxylem vessels are always located at the outer position of two to four metaxylem vessels. Thus, xylem differentiation is strictly controlled to produce and maintain the correct spatial arrangement of two different vessels in the root vascular system and therefore has provided a paradigm of spatial regulation of plant development ([@B9], [@B22]).

Plant hormones such as auxins, brassinosteroids and cytokinins are crucial intercellular signaling molecules that control the differentiation and proliferation of vascular cells ([@B9]). Of the plant hormones, cytokinins play crucial and pleiotropic roles in vascular development including enhancement of procambial/cambial proliferation and suppression of protoxylem vessel formation ([@B22], [@B45], [@B26], [@B31], [@B10]). It is also known that the regulation of vascular cell fate involves the function of specific components of the two-component system, wherein cytokinin receptors transduce the signal through Arabidopsis histidine phosphotransfer proteins (AHPs) to Arabidopsis response regulators (ARRs) via phosphorylation ([@B23], [@B12], [@B22], [@B45]).

Screening of extracellular factors using *Zinnia* cultured cells has revealed a new player, tracheary element differentiation inhibitory factor (TDIF), a dodeca-amino acid secretory peptide ([@B15]). TDIF acts in local cell--cell communication during vascular development ([@B11]). TDIF belongs to the CLAVATA3/EMBRYO SURROUNDING REGION-related (CLE) family, which contains 32 members in Arabidopsis ([@B16]). Indeed, it has been reported that *CLE19* functions in early xylem development ([@B7]). Furthermore, [@B42] reported that overexpression of some CLE genes (CLE6, CLV3 and CLE19) could cooperate with TDIF to enhance vascular proliferation. Therefore, not only TDIF but also other CLE peptides may play some roles in cell communication involved in vascular development.

In this report, we found a novel function of CLE peptides in vascular development in Arabidopsis roots. Comprehensive analyses of CLE peptides revealed that some CLE peptides, including CLE10, suppressed protoxylem vessel formation, similarly to cytokinin. Microarray analysis and genetic analyses indicated that this suppression by the CLE peptides occurred through activation of cytokinin signaling. These results suggest that there is cross-talk between CLE peptide signaling and cytokinin signaling in protoxylem vessel formation.

Results
=======

CLE peptides causing inhibition of protoxylem development in roots
------------------------------------------------------------------

To understand the function of Arabidopsis CLE peptides in vascular development, we examined the effect of exogenously supplied 26 dodeca-peptides on vascular development in the primary root and lateral roots. Xylem in roots contains two different vessels: metaxylem and protoxylem ([Fig. 1A](#F1){ref-type="fig"}). Treatment with some CLE peptides at 1 μM inhibited formation of protoxylem vessels but not of metaxylem vessels, in both the primary root ([Fig. 1B--H](#F1){ref-type="fig"}) and lateral roots ([Supplementary Fig. S1](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1)). In a series of experiments, defects of vessel formation occurred similarly both in the primary root and lateral roots, although protoxylem vessel formation in lateral roots seems to be affected by a lower concentration of CLE10 than that in the primary roots (e.g. [Fig. S1C compared with D](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1)). Because of easier and more accurate quantification of vascular defects in the primary root than in lateral roots, we usually used the primary root for evaluating vascular defects. Previous studies have revealed that 19 of 26 Arabidopsis CLE dodeca-peptides inhibit root growth ([@B15], [@B19]). We found that 17 of these 19 CLE peptides inhibited protoxylem vessel formation without affecting metaxylem vessel formation ([Figs. 1D, E, H](#F1){ref-type="fig"}, [2A, B](#F2){ref-type="fig"}). Interestingly, CLE25 and CLE26, which most severely inhibit root growth ([@B19]), were much less effective against protoxylem vessel formation ([Fig. 1F](#F1){ref-type="fig"}). These defects were enhanced in a dose-dependent manner as shown by the experiment with CLE9/10 peptide (hereafter referred to as CLE10 peptide), although a control peptide (CLE25) treatment had little effect on protoxylem vessel formation even at the highest concentration ([Fig. 3A--D](#F3){ref-type="fig"}). These results suggest that CLE peptides function in protoxylem formation directly, but not indirectly through a root growth defect. CLE-induced vascular defect occurred in one or both of the two protoxylem vessel cell files. In most cases, one file was almost completely lost ([Fig. 1D, E](#F1){ref-type="fig"}), and the other was partially disrupted ([Fig. 2C--E](#F2){ref-type="fig"}). Interestingly, the seven CLE peptides that do not inhibit root growth, including TDIF (CLE41/44), did not cause defects in protoxylem vessel formation ([Fig. 1G, H](#F1){ref-type="fig"}). Fig. 1Effects of CLE peptides on protoxylem vessel formation and growth in the primary root. (A) A schematic vascular structure in Arabidopsis roots. Red and blue arrowheads represent protoxylem and metaxylem cell files, respectively. (B--H) Arabidopsis seeds were germinated in liquid medium with one of 26 dodeca-amino acid CLE peptides at 1 μM. Seven-day-old seedlings were collected to observe root growth and protoxylem vessel formation in roots. (B--G) Effects on protoxylem vessel formation of no peptide (B), CLE1/3/4 (C), CLE9/10 (D), CLV3 (E), CLE25 (F) and TDIF (G). (H) Twenty-six CLE peptides were classified into three groups (blue, red and orange frames) depending on their effects on the suppression of root growth and protoxylem vessel formation. Asterisks indicate synonymous names for the same peptide. For example, CLE1/3/4 means the same peptide derived from three different *CLE1*, *CLE3* and *CLE4* genes. Root growth and protoxylem formation were represented as inhibited (+) or not inhibited (−). (I--K) Vascular-specific expression of *CLE9* and *CLE10* in the primary root. GUS activity was observed in the root of Arabidopsis seedlings harboring a chimeric gene of the promoter of a *CLE* gene and the *GUS* gene. (I) *CLE9*~pro~*:GUS*. (J) *CLE10*~pro~*:GUS*. (K) is a cross-section of (J). Scale bars are 25 μm. Fig. 2Confocal sections of the root vasculature. Confocal images of the protoxylem vessels and metaxylem vessels were taken from the mPS--PI-stained primary root of seedlings treated with 1 μM CLE10. (A) A bright field image. (B) A radial optical section of (A), which was constructed from Z-stack images by using image J (<http://rsbweb.nih.gov/ij/>). (C) A longitudinal image of a partially disrupted protoxlem vessel. (D, E) Radial optical sections of (C) at the green line position (D) and at the blue line position (E). Red and blue indicate protoxylem and metaxylem vessels, respectively. Orange indicates a cell where differentiation into protoxylem vessels has been inhibited. Scale bars are 25 μm. Fig. 3CLE10 peptide-dependent suppression of protoxylem vessel formation in mutants defective in cytokinin signaling. (A--C, E--G, I--K) The WT, *arr10-5 arr12-1* and *ahp6-1* seedlings were grown for 7 d on agar plates (with 0.8% agar) containing no peptide, 1 μM CLE10 and 1 μM CLE25. (D, H, L) Dose-dependent suppression of protoxylem vessel formation by CLE10. The WT (D), *arr10-5 arr12-1* (H) and *ahp6-1* (L) seedlings were grown for 7 d on plates with no peptide, 10--1000 nM CLE10 and 1000 nM CLE25, and classified into three types depending on the phenotype of protoxylem vessels in the primary root. Black represents normal protoxylem vessel formation where two protoxylem cell files differentiated correctly. Gray represents a weak abnormal phenotype showing that one of the two protoxylem cell files was missing or interrupted. White represents a severe abnormal phenotype showing that both protoxylem cell files were missing or interrupted. (*N* = 19--30). Scale bars are 25 μm.

Vascular-specific expression of *CLE9* and *CLE10* genes in roots
-----------------------------------------------------------------

To determine which CLE peptides function in protoxylem differentiation in situ, we screened for CLE genes involved in vascular development based on expression data of the Arabidopsis in vitro xylogenic culture system (see expression data in [@B20]). We found that transcripts for two *CLE* genes (*CLE10* and *CLE26*) increased in the early stages of xylem differentiation. Because CLE26 peptide was not involved in protoxylem vessel formation as aforementioned, we focused on the *CLE10* gene. We then examined the expression pattern of *CLE10* in Arabidopsis seedlings harboring a chimeric gene of its promoter and the β-glucuronidase (GUS) reporter gene (*CLE10*~pro~*:GUS*). We also analyzed the expression of *CLE9*~pro~*:GUS*, because *CLE9* encodes the same CLE dodeca-peptide as *CLE10* ([@B15]). Both genes exhibited stele-specific expression in roots ([Fig. 1I, J](#F1){ref-type="fig"}), in particular in the differentiation zone (DZ) and the elongation zone (EZ) near the root basal meristem (RBM) ([Supplementary Fig. S2A, B](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1)). Transverse sections of roots revealed ubiquitous expression of *CLE10* in the stele ([Fig. 1K](#F1){ref-type="fig"}).

CLE10 peptide regulates protoxylem vessel formation
---------------------------------------------------

Some CLE peptides take their active form after post-translational glycosylation ([@B32]). Therefore the result of exogenous CLE10 peptide treatment might not reflect the function of endogenous CLE10 peptide. To examine whether the *CLE10* gene is capable of inhibiting protoxylem vessel formation in vivo, we overexpressed *CLE10* using an estradiol-inducible system ([@B6]). In the presence of estradiol, these transgenic plants exhibited the same protoxylem vessel defect as plants treated with CLE10 peptide ([Fig. 4](#F4){ref-type="fig"}). These results strongly suggest that chemically synthesized CLE10 dodeca-peptide reflects the function of endogenous CLE10 peptide in the inhibition of protoxylem vessel formation. Fig. 4Effects of *CLE10* overexpression on root growth and protoxylem vessel formation. The WT (Col-0) and *XVE:CLE10-*harboring seedlings were grown on agar plates (with 1.5% agar) for 7 d with (+) or without (−) 5 μM estradiol. (A) Inhibition of root growth by overexpression of *CLE10*. Scale bar is 5 mm. (B) Inhibition of protoxylem vessel formation by overexpression of *CLE10*. Black, gray and white bars are explained in [Fig. 3](#F3){ref-type="fig"} (*N* = 12--14). (C, D) Images of root vessels in the WT (C) and *XVE:CLE10-*harboring (D) seedlings, when treated with and without estradiol. Scale bars are 25 μm.

Protoxylem vessel formation is initiated by VND7, a master transcription factor ([@B20]). To reveal whether CLE10 peptide affects the initiation step of protoxylem vessel formation or later stages of the differentiation, we examined the effect of CLE10 on the expression of *VND7*~pro~*:YFP* in roots. The fluorescence signal of *VND7*~pro~*:YFP* was detected in two cell files in the RBM and EZ in this line, as previously reported ([@B44]). Interestingly, CLE10 treatment reduced expression levels of *VND7*~pro~*:YFP* in the RBM when compared with CLE25 treatment ([Fig. 5A--D](#F5){ref-type="fig"}). These results suggest that CLE10 inhibits an early stage of protoxylem development. Fig. 5Inhibition of *VND7pro:YFP* expression by CLE10 peptide. (A--D) Seedlings were grown for 5 d in liquid medium with 1 μM CLE10 (A, C) or CLE25 (B, D). Fluorescence from *VND7pro:YFP* was detected in the non-stained primary root under a fluorescence microscope (A, B), and in the PI-stained primary root under a confocal microscope (C, D). White arrowheads represent the boundary between the RBM and the EZ. Scale bars are 50 μm.

Interaction between cytokinin and CLE10 signaling in regulating protoxylem differentiation
------------------------------------------------------------------------------------------

It has been reported that cytokinin also inhibits protoxylem vessel differentiation ([@B22], [@B45]). To examine the interaction between cytokinin and CLE10 signaling, we performed a GeneChip analysis of transcripts from CLE10 peptide-treated roots with the Arabidopsis 23K chip. CLE25 peptide treatment was used as a control, because it repressed root growth without affecting protoxylem vessel formation. A subset of the genes differentially expressed between CLE10- and CLE25-treated seedlings should be involved in the regulation of protoxylem vessel formation. The GeneChip analysis has uncovered that only four genes, *ARR5*, *ARR6*, *adenylate isopentenyltransferase 7* (*IPT7*) and *cytokinin oxidase 3* (*CKX3*) are significantly and reproducibly decreased upon CLE10 treatment ([Fig. 6A](#F6){ref-type="fig"}, [Supplementary Table S1](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1)). However, CLE10 treatment upregulated significantly no cytokinin-related genes. Both ARR5 and ARR6 belong to type-A ARRs, which act as negative regulators in cytokinin signaling ([@B39]). On the other hand, IPT7 and CKX3 act in cytokinin synthesis and degradation, respectively ([@B17], [@B28], [@B37]). These results suggest that CLE10 may modulate endogenous cytokinin levels and/or cytokinin signaling by affecting the expression levels of cytokinin-related genes. Fig. 6Cross-talk between type-A ARRs and CLE10 signaling in protoxylem vessel formation. (A, B) Reduction of transcript levels of cytokinin-related genes including type-A *ARR*s by CLE10 peptide. Arabidopsis seedlings were grown in liquid medium containing 1 μM CLE10 or 1 μM CLE25 for 3--12 h, and transcript levels of cytokinin-related genes were measured by GeneChip (A) or with quantitative PCR (B). (A) Expression levels of four genes (*ARR5*, *ARR6*, *IPT7* and *CKX3*) were significantly decreased by 12 h treatment of CLE10. The fold change was calculated as the ratio of transcript levels of plants treated with CLE10 compared with CLE25 (in log2 scale). Asterisks indicate statistically significant differences (*P* \< 0.1). (B) Changes in two type-A *ARR* transcripts by 3, 6 and 12 h treatment of 1 μM CLE10 or CLE25. *ACT2* was used as a control. The relative expression was calculated as the ratio of transcript levels of plants treated with CLE10 when compared with CLE25. Asterisks indicate statistically significant differences (*P* \< 0.01). (C, D) *ARR5* expression levels of plants treated with no peptide, 1 μM CLE10 or 1 μM CLE25 for 6 h in the WT (C) or *clv2* (D). The relative expression was calculated as the ratio of transcript levels of plants treated with CLE peptides when compared with no peptide. Asterisks indicate statistically significant differences when compared with no peptide treatment (*P* \< 0.01). (A--D) Error bars represent SD (*N* = 3). (E--G) Defects in protoxylem vessel formation in lateral roots. (E, F) Protoxylem vessel formation in lateral roots of 8-day-old WT and *arr5 arr6* seedlings. (G) The frequency of suppressed protoxylem vessel formation in lateral roots of WT, *arr5*, *arr6*, *arr5 arr6* (*N* = 32--53). One to four lateral roots located next to the hypocotyl, per seedling, were used for measurement. Scale bars are 25 μm.

The *ahk2 ahk4* mutant is sensitive to CLE10 in protoxylem vessel formation
---------------------------------------------------------------------------

Cytokinins are perceived by three Arabidopsis histidine kinase (AHK) receptors, and upon activation the signal is transduced by a phosphorelay to downstream components ([@B13], [@B36], [@B41], [@B43]). To investigate whether an increase in cytokinin levels by CLE10 contributes to the protoxylem vessel defects, we examined the effect of CLE10 peptide on protoxylem vessels in a cytokinin receptor mutant. The *ahk2 ahk4* mutant was sensitive to the effects of CLE10 on protoxylem vessel formation when compared with the effects of benzyladenine (BA), while the wild type (WT) showed high sensitivity to both CLE10 and BA ([Fig. 7A, B](#F7){ref-type="fig"}). In addition, this inhibition by CLE10 in the double mutant occurred in a dose-dependent manner, although the inhibition was not as severe as that in the WT ([Fig. 7A, B](#F7){ref-type="fig"}). These results suggest that CLE10 may modulate not endogenous cytokinin levels but intracellular cytokinin signaling. Fig. 7Effects of BA and CLE10 peptide on protoxylem vessel formation in *ahk2 ahk4*, *clv2* and *crn*. (A, B) Seedlings of WT (A) and *ahk2 ahk4* (B) were grown in liquid medium containing BA and CLE10 at 10, 100 or 1000 nM for 7 d. (C--F) Seedlings of WT (Col-0) (C), *clv2* (D), WT (Utr) (E) and *crn* (F) were treated with no peptide, BA or CLE10 at 1000 nM for 7 d. Black, gray and white bars are explained in [Fig. 3](#F3){ref-type="fig"} (*N* = 12--18).

Expression levels of type-A *ARR*s are rapidly decreased by CLE10 treatment
---------------------------------------------------------------------------

Next, we examined the role of the type-A ARRs. Because type-A ARRs act as negative regulators of cytokinin signaling ([@B18], [@B38], [@B39], [@B33]), the repression of type-A ARRs by CLE10 may lead to the activation of cytokinin signaling and consequently inhibit protoxylem differentiation. We quantified the effect of CLE10 on the expression of type-A *ARR*s. Transcript levels of two type-A *ARR*s (*ARR5* and *ARR6*) were significantly decreased by CLE10 ([Fig. 6B](#F6){ref-type="fig"}; *P* \< 0.01), which is consistent with the GeneChip analysis. This decrease occurred as early as 6 h after CLE10 treatment ([Fig. 6B](#F6){ref-type="fig"}). In contrast, CLE25 treatment did not alter transcript levels of *ARR5* when compared with the result from the treatment without peptide ([Fig. 6C](#F6){ref-type="fig"}).

To investigate whether the decreased expression of these two type-A *ARR*s (*ARR5* and *ARR6*) by CLE10 contributes to the protoxylem vessel defects, we observed the primary root and lateral roots of the single *arr5* or *arr6* null mutant and the *arr5 arr6* double null mutant. Each single mutant exhibited no obvious defect in protoxylem vessel formation in the primary root and lateral roots ([Fig. 6E--G](#F6){ref-type="fig"}). However, the *arr5 arr6* double mutant occasionally displayed the loss of protoxylem vessels in lateral roots but not in the primary root ([Fig. 6E--G](#F6){ref-type="fig"}, [Supplementary Fig. S1](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1)). In addition, *arr5 arr6* was more sensitive to CLE10 than the WT in protoxylem vessel formation in both the primary root and lateral roots ([Supplementary Fig. S1](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1)). These results suggest that *ARR5* and *ARR6* may be downstream components of CLE10 signaling to cause protoxylem vessel defects, although another factor (or factors), probably another type-A *ARR*(s) is also involved in its signaling.

CLE10 causing enhancement of cytokinin signaling suppresses protoxylem vessel formation
---------------------------------------------------------------------------------------

Type-B ARRs are transcription factors that act as positive elements in cytokinin signaling to mediate cytokinin-regulated gene expression, including the transcriptional induction of type-A *ARR*s in response to cytokinin ([@B45]). Because type-A ARRs and type-B ARRs probably compete with each other for phosphotransfer ([@B38]), the repression of type-A *ARR* expression by the CLE10 peptide may activate type-B ARR activities, which will in turn cause cytokinin- dependent suppression of protoxylem vessel formation. Two type-B ARRs, ARR10 and ARR12, are key transcription factors mediating the effect of cytokinin on root vascular development ([@B1]). Cytokinin does not inhibit protoxylem vessel differentiation in an *arr10-5 arr12-1* double null mutant ([@B45], [@B1]). We then examined the effect of CLE10 on protoxylem vessel formation in the *arr10-5 arr12-1* double mutant. Similarly, CLE10 did not suppress protoxylem vessel formation in the *arr10-5 arr12-1* mutant roots ([Fig. 3E--H](#F3){ref-type="fig"}). Other type-B ARR double mutants (*arr1-4 arr10-5* and *arr1-4 arr12-1*) showed weaker resistance to CLE10 in protoxylem vessel formation ([Fig. 8A](#F8){ref-type="fig"}). In contrast, CLE10 peptide still inhibited root growth in *arr10-5 arr12-1* ([Fig. 8B--D](#F8){ref-type="fig"}), suggesting that root growth suppression by CLE10 is independent of these type-B ARRs. These results indicate that *ARR10* and *ARR12* are necessary for the CLE10-mediated suppression of protoxylem formation. Furthermore, these results are consistent with the notion that CLE10 peptide inhibits protoxylem vessel formation by activating cytokinin signaling through repression of the expression of type-A *ARR*s. Fig. 8Different sensitivities to CLE10 among three type-B *ARR* double mutants. (A) Seedlings of *arr1 arr12*, *arr1 arr10* and *arr10 arr12* were grown in liquid medium with or without 1 μM CLE10 for 7 d, and the numbers of primary roots with defects in protoxylem vessels was counted. Black, gray and white bars are explained in [Fig. 3](#F3){ref-type="fig"} (*N* = 7--12). (B--D) CLE10-induced root growth inhibition in *arr10 arr12*. The WT and *arr10 arr12* seedlings were grown for 7 d on agar plates (with 1.5% agar) containing no peptide and 10--1000 nM CLE10. (A, B) Seedlings of the WT (A) and *arr10 arr12* (B) grown with no peptide (left) and with 1 μM CLE10 (right). (C) Root length in WT and *arr10 arr12* seedlings. Error bars represent SD (*N* = 7--11).

CLE10 activates cytokinin signaling via an AHP6-independent pathway
-------------------------------------------------------------------

[@B22] reported that the *ahp6-1* mutation inhibits protoxylem vessel formation, and the pseudophosphotransfer protein AHP6, which interferes with phosphotransfer from AHKs to AHPs in cytokinin signaling, promotes the formation of protoxylem vessel. To more closely examine the relationship between cytokinin and CLE10 signaling, we tested the effect of CLE10 on protoxylem vessels in the *ahp6-1* mutant. CLE10 peptide enhanced suppression of protoxylem vessel formation in *ahp6-1* ([Fig. 3I--L](#F3){ref-type="fig"}), suggesting that CLE10 signaling acts at least partially independently of AHP6- mediated cytokinin signaling pathways.

CLE10 inhibits protoxylem vessel formation via CLV2
---------------------------------------------------

Plants defective in the receptor for the CLE10 peptide should be insensitive to exogenous CLE10. Therefore, we analyzed the effect of CLE10 on protoxylem vessel formation in a series of T-DNA insertion lines of the CLE receptor, CLV2, and many members of subclass XI of the leucine-rich repeat receptor-like kinase (LRR-RLK) family, including CLV1 and TDIF receptor (TDR/PXY) ([@B8], [@B11], [@B4]). Of these, only the *clv2* null mutant exhibited insensitivity to CLE10 in the suppression of protoxylem vessel formation ([Fig. 7C, D](#F7){ref-type="fig"}). Indeed, *ARR5* expression level in the *clv2* mutant was also resistant to CLE10 ([Fig. 6C, D](#F6){ref-type="fig"}). Interestingly, in *clv2* roots, the ectopic protoxylem vessels were formed in the DZ where metaxylem vessels had not yet differentiated ([Fig. 9D--G](#F9){ref-type="fig"}). The cytokinin receptor mutant *ahk2 ahk4* and type-B ARR mutant *arr10 arr12* also produced ectopic protoxylem vessels, although these mutants produced them more frequently than the *clv2* mutant ([Fig. 9A--E](#F9){ref-type="fig"}). These results indicate that endogenous CLV2 functions in the suppression of protoxylem vessel formation and mediates CLE10 signaling. Fig. 9Ectopic protoxylem vessel formation in the primary root of mutants. (A--D) Protoxylem vessel formation in the WT (A), *ahk2 ahk4* (B), *arr10 arr12* (C) and *clv2* (D). Arabidopsis roots exhibit diarch symmetry of the vascular bundle in which a protoxylem vessel file per arch is formed. However, *ahk2 ahk4*, *arr10 arr12* and *clv2* roots often have two or three protoxylem vessel files per arch. (E) The frequency of the primary root with ectopic protoxylem vessel files in the WT, *ahk2 ahk4*, *arr10 arr12* and *clv2* (*N* = 32--33). (F, G) Confocal images of the primary root of *clv2*. (F) A bright field image of the mPS--PI-stained stele. (G) An optical section of (F). Red and green indicate protoxylem vessels and phloem cells, respectively. Blue indicates undifferentiated metaxylem vessel cells. (H) Protoxylem vessel phenotypes in the primary root caused by loss-of-function and gain-of-function of CLE and cytokinin signaling. Circles show the root stele. Red indicates the area that protoxylem vessel cells occupy. *CLE10*o/x shows plants in which *CLE10* is overexpressed. Scale bars are 25 μm.

CLV2 cannot function alone as a receptor kinase, because of lack of an intracellular kinase domain. It has been proposed that in the CLV3 signaling pathway, a protein kinase CORYNE (CRN)/suppressor of LLP2 (SOL2), which carries a transmembrane domain and a short extracellular domain, possibly functions as a heterodimer with CLV2 in the shoot apical meristem (SAM) ([@B29], [@B27], [@B2], [@B47]). Therefore we examined the CLE10 sensitivity of the *sol2-1* mutant. This mutant showed insensitivity to exogenous CLE10 in protoxylem vessel formation ([Fig. 7E, F](#F7){ref-type="fig"}). Because *CRN/SOL2* is expressed in the root stele ([@B29]), CLV2 may function together with CRN in the CLE10 signaling pathway regulating protoxylem development, as in the CLV3 signaling pathway in SAM.

Discussion
==========

Novel function of CLE peptides in vascular development
------------------------------------------------------

In this study, we found that CLE peptides including CLE10 inhibited protoxylem vessel formation in roots as well as root growth, while CLE25 and CLE26 repressed root growth without inhibiting protoxylem vessel formation. However, TDIF, which inhibits vessel differentiation in leaves and hypocotyls ([@B15]), did not affect protoxylem vessel formation in roots or root growth. These results suggest that the machinery underlining vessel development may differ between roots and leaves/hypocotyls. Further comprehensive analyses indicated that the CLE10-dependent suppression of protoxylem vessel formation in roots is an important regulatory machinery, which activates cytokinin signaling, and is not the secondary effect of the repression of root growth.

Type-A ARRs including ARR5 and ARR6, positively regulate protoxylem vessel formation in the CLE10 signaling pathway
-------------------------------------------------------------------------------------------------------------------

The analysis with GeneChip and quantitative real-time reverse transcription (RT)--PCR revealed that CLE10 treatment significantly reduced transcripts of *ARR5* and *ARR6*, which share high similarity and function as negative regulators in cytokinin signaling ([@B18], [@B38], [@B39], [@B33]). In lateral roots of a double mutant but not of single mutants of *arr5* and *arr6*, protoxylem vessel formation was strongly inhibited, indicating that *ARR5* and *ARR6* function in the promotion of protoxylem vessel formation redundantly. This result is consistent with the idea that the downregulation of *ARR5* and *ARR6* by CLE10 peptide causes the suppression of protoxylem vessel formation. However, the facts that the suppression of protoxylem vessel formation in *arr5 arr6* is weaker than that in CLE10-treated plants and that protoxylem vessel defects in *arr5 arr6* are not observed in the primary root suggest the contribution of other type-A ARRs to protoxylem vessel formation.

CLE10 has little effect on the suppression of protoxylem vessel formation in the double type-B ARR mutant, *arr10 arr12*, which supports the idea that CLE10 regulates protoxylem vessel formation through cytokinin signaling. ARR1, ARR10 and ARR12 are major members of the type-B ARR family, which function as positive transcription factors in cytokinin signaling ([@B25]). Indeed, the triple mutant *arr1 arr10 arr12* shows high resistance to exogenous cytokinin ([@B1], [@B14]). Our results indicated that *arr10 arr12* was the most resistant of all type-B *ARR* double mutants (*arr1 arr10*, *arr1 arr12* and *arr10 arr12*) against CLE10 in terms of the inhibition of protoxylem development. This is consistent with the observation that the cytokinin-causing vascular defect is overcome more effectively in *arr10 arr12* than in *arr1 arr12* and *arr1 arr10* ([@B1]). Taken together with the fact that *ARR10* and *ARR12* are expressed in the root stele ([@B24], [@B45]), we present a model that cross-talk between CLE10 peptide and cytokinin signaling via type-B ARRs (ARR10 and ARR12) and type-A ARRs (ARR5 and ARR6) regulates protoxylem vessel development in roots ([Fig. 10](#F10){ref-type="fig"}). Fig. 10A model illustrating the cross-talk between cytokinin and CLE peptide signaling pathways to suppress protoxylem vessel formation. CLE peptides positively regulate cytokinin signaling via type-A ARRs in protoxylem vessel formation. Blue and red lines indicate phosphorylational and transcriptional regulation, respectively.

CLE peptides and cytokinins may suppress the initiation of protoxylem vessel formation in the root meristem
-----------------------------------------------------------------------------------------------------------

Generally, the initiation of protoxylem vessel formation occurs in the root meristem ([@B5]). Most of the genes encoding signaling components that we found as key regulators of protoxylem vessel formation (*CLV2*, *CRN*, *ARR5*, *ARR6*, *ARR10* and *ARR12*) were expressed in the RBM ([Supplementary Fig. S2C--I](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1)). Furthermore, the CLE10 peptide could suppress the expression of *VND7*, which directs protoxylem differentiation, in the RBM. Considering that *CLE9* and *CLE10* genes are expressed in vascular tissues of the EZ near the RBM ([Supplementary Fig. S2A, B](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1)), CLE10 peptide might move down to the RBM and inhibit protoxylem vessel formation in the procambium, together with other factors such as ARRs and CLV2.

Ectopic protoxylem vessel formation in *clv2* and some mutants of cytokinin-related genes occurred in procambial cells adjacent to original protoxylem vessels, but not in metaxylem vessel cell files ([Fig. 9A--G](#F9){ref-type="fig"}). This ectopic differentiation from procambial cells is also observed in *ahk3 ahk4* ([@B22]). In more severe cytokinin mutants such as *woodenleg* (*wol*) and a type-B *ARR* triple mutant, not only procambial cells adjacent to original protoxylem vessels but also most procambial and metaxylem precursor cells differentiate into protoxylem vessels ([Fig. 9H](#F9){ref-type="fig"}) ([@B45], [@B14]). In contrast, the supply of cytokinin and CLE10 and *CLE10* overexpression reduced the number of protoxylem vessels. Therefore, it is probable that basically cytokinin signaling inhibits protoxylem vessel formation in the whole root stele and CLE peptide signaling modulates cytokinin signaling locally ([Fig. 9H](#F9){ref-type="fig"}).

Relationships between CLE peptides and type-A ARRs
--------------------------------------------------

Similar cross-talk between CLE signaling and type-A ARRs has been reported in SAM maintenance, in which the transcription factor WUSCHEL (WUS) acts downstream of CLV3 signaling ([@B35]). WUS directly represses the expression of several type-A *ARR*s (*ARR5*, *ARR6*, *ARR7* and *ARR15*) in SAM ([@B21]). These suggest that CLE peptides may commonly regulate cytokinin signaling through type-A ARRs during plant development, although signaling pathways of many other CLE peptides remain to be elucidated. WUS also upregulates *CLV3* expression in SAM maintenance through a negative feedback ([@B3]). In crown root development, OsWOX11 (WUS-related HOMEOBOX), which is a rice homolog of Arabidopsis WOX11, directly represses *RR2*, a type-A response regulator gene ([@B46]). However, our GeneChip analysis revealed that no *CLE* or *WOX* gene was induced by CLE10 peptide application. Therefore, although some type-A ARRs may play a role as downstream factors of CLE signaling pathways, the mechanisms by which type-A ARRs are induced may vary.

Materials and Methods
=====================

Plant materials and growth conditions
-------------------------------------

All *Arabidopsis thaliana* plants other than *sol2-1* (Utr background) were of Col-0 background. Arabidopsis seeds were grown on 1/2 Murashige and Skoog (MS) agar plates or liquid medium with or without CLE peptides at 22°C. CLE peptides were obtained and stored as described previously ([@B15]). *ahp6-1* seeds were a gift from Dr Ykä Helariutta (Helsinki University) ([@B22]), *arr1-4 arr10-5*, *arr1-4 arr12-1* and *10-5 arr12-1* seeds from Dr Takafumi Yamashino (Nagoya University) ([@B45]), *clv2* seeds (GABI_686A09) from Dr Sumie Ishiguro (Nagoya University) ([@B34]), *ahk2 ahk4* (*ahk2-2tk cre1-12*) seeds from Dr Tatsuo Kakimoto (Osaka University) ([@B22]), *sol2-1* seeds from Dr Shinichiro Sawa ([@B27]) and *VND7*~pro~*:YFP* seeds from Dr Kyoko Ito-Ohashi. Type-A *ARR* mutants were described previously ([@B38]).

To generate the *CLE* promoter:GUS reporter constructs, we used an approximately 1--2 kb DNA fragment upstream of the predicted start codon of each gene. Primer sets used are listed in [Supplementary Table S2](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1). Expression of the *CLE promoter:GUS* was observed in T2 or T3 plants. GUS staining was performed according to a previous protocol ([@B30]).

The *CLE10* coding sequence was cloned into the pMDC7 vector ([@B6]) to generate *XVE:CLE10*, and introduced into Arabidopsis plants. The phenotype was observed with T3 plants. Primer sets used are listed in [Supplementary Table S2](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1).

Observation of vasculature
--------------------------

Roots were fixed in a 1:3 mixture of acetic acid/ethanol and mounted in a mixture of chloral hydrate/glycerol/water (8:1:2) and observed under a light microscope (BX51; Olympus, Tokyo, Japan). Sectioning was performed as previously described ([@B11]).

mPS--PI staining
----------------

Modified pseudo-Schiff--propidium iodide (mPS--PI) staining was performed as previously described ([@B40]). Samples were observed under an inverted fluorescent microscope (IX70; Olympus) equipped with a confocal unit (CSU10; Yokogawa, Tokyo, Japan).

Microarray analysis
-------------------

We treated 7-day-old seedlings with 1 μM CLE10 or CLE25 (a control peptide) for 12 h. After treatment, total RNA was extracted from about 100 root tips (5 mm in length). RNA extraction and purification were performed as described previously ([@B27]). GeneChip analyses were independently performed three times with the Arabidopsis ATH1 Genome Array (Affymetrix, Santa Clara, CA, USA) as described in the GeneChip Expression Analysis Technical Manual. Comparison analysis of samples treated with CLE25 and CLE10 was performed with the GeneChip Operating Software.

Real-time PCR
-------------

Total RNA was extracted from whole main roots of 7-day-old seedlings treated with mock or CLE peptides. Quantitative PCR was performed independently three times by Light Cycler (Roche Diagnostics, Indianapolis, IN, USA). As the internal control, the tubulin α4 gene was used. Gene-specific primer sets used are listed in [Supplementary Table S2](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1).

Supplementary Data
==================

[Supplementary data](http://pcp.oxfordjournals.org/cgi/content/full/pcq129/DC1) are available at PCP Online.
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AHK

:   Arabidopsis histidine kinase

AHP

:   Arabidopsis phosphotransfer protein

ARR

:   Arabidopsis response regulator

BA

:   Benzyladenine

CKX3

:   cytokinin oxidase 3

CLE

:   CLAVATA3/EMBRYO SURROUNDING REGION-related

CRN

:   CORYNE

DZ

:   differentiation zone

EZ

:   elongation zone

GUS

:   β-glucuronidase

IPT7

:   adenylate isopentenyltransferase 7

LRR-RLK

:   leucine-rich repeat receptor-like kinase

mPS--PI

:   modified pseudo-Schiff--propidium iodide

RBM

:   root basal meristem

RT--PCR

:   reverse transcription--PCR

SAM

:   shoot apical meristem

SOL2

:   suppressor of LLP2

TDIF

:   tracheary element differentiation inhibitory factor

WT

:   wild type

WUS

:   WUSCHEL.
